Another Potential Blockbuster for Johnson & Johnson Investors

A new class of diabetes drugs called SGLT-2 inhibitors -- which block the natural reabsorption of excess glucose in the bloodstream and allow it to pass out of the body -- could potentially be huge in the type 2 diabetes space, and Johnson & Johnson (NYSE: JNJ  ) recently received a 10-5 recommendation for approval for its SGLT-2 inhibitor Invokana from an FDA advisory committee. If approved, JNJ would be the first to market in the United States with this type of drug, which could be a nice win for the company.

In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.